A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.

Phase 1

Proacta, Incorporated